AmitBar-OrMD

Neurology • Philadelphia, PA

Neuroimmunology/Multiple Sclerosis

Director, Center for Neuroinflammation and Neurotherapeutics Chief, Multiple Sclerosis Division

Join to view full profile

Dr. Bar-Or is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bar-Or's full profile

Already have an account?

Office
3400 Civic Center Boulevard
Philadelphia, PA 19104
Phone+1 215-220-9384

Education & Training

Harvard Medical SchoolImmunology, 1997 - 2000
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1993 - 1997
McGill University Faculty of MedicineClass of 1993

Certifications & Licensure

PA State Medical License 2016 - 2026
MA State Medical License 1997 - 2001

Clinical Trials

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis Start of enrollment: 2017 Oct 19
Terminated
Phase 1, Phase 2
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Start of enrollment: 2021 Aug 13
Completed
Phase 2
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) Start of enrollment: 2019 Dec 19
Recruiting
Phase 3

Publications & Presentations

PubMed

Reliability of Central Vein Sign Imaging With 3T FLAIR* in a Multicenter Study.
Melissa Lynne Martin, Quy Cao, Elaina Luskin, Brian Renner, Lynn Daboul
Journal of Neuroimaging. 2025-01-22
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.
Vivien Li, Fiona C McKay, David C Tscharke, Corey Smith, Rajiv Khanna
CNS Drugs. 2025-01-10
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy.
Patrick Vermersch, Ralf Gold, Amit Bar-Or, Bruce A C Cree, Robert J Fox
Multiple Sclerosis and Related Disorders. 2025-01-04

Journal Articles

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis
Myla D Goldman, Amit Bar-Or, JAMA Neurology
Ofatumumab Versus Teriflunomide in Multiple Sclerosis
Stephen L Hauser, Amit Bar-Or, Patricia K Coyle, Alexandra Goodyear, The New England Journal of Medicine

Authored Content

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients with Relapsing-Remitting Multiple SclerosisAugust 2020
Ofatumumab Versus Teriflunomide in Multiple SclerosisAugust 2020
Ofatumumab Versus Teriflunomide in Multiple SclerosisAugust 2020

Press Mentions

B Cells Drive Responses of Other Immune Cells, and Can Be Modified to Prevent Multiple Sclerosis SymptomsMay 3rd, 2024
Even When Undergoing Treatment, People with MS Gain from COVID VaccinesSeptember 16th, 2021
With Remarkable Similarities to MS, a Disease in Dogs Opens New Avenues for StudyJune 29th, 2021
Join now to see all